Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder

**Question**

*Question*: Is atypical antipsychotic use associated with incident diabetes or hyperlipidaemia in older people without schizophrenia or bipolar disorder?

*People*: Medicare advantage or commercial managed healthcare plan enrollees aged 65 and above with no history of schizophrenia, bipolar disorder, diabetes (for the hyperlipidaemia study) or hyperlipidaemia (for the diabetes study) in the previous year. In the diabetes study, cases were 13 075 people who initiated diabetes treatment between 2004 and 2008 (identification period), and controls were 65 375 people who had not received diabetes treatment during this time. In the hyperlipidaemia study, cases were 65 829 people newly started on hyperlipidaemia medication, and controls were 65 829 people who had not received hyperlipidaemia medication. Controls were matched to cases based on age, sex, health plan type and index date. The index date for cases was the date of first diabetes or hyperlipidaemia medication prescription fill. For controls, the index date was a randomly selected date in the identification period.

*Setting*: USA; from 2003 to 2008.

*Risk factors*: Atypical antipsychotic exposure in the year prior to diabetes or hyperlipidaemia treatment initiation (preindex period), identified using pharmacy claims data. Medications considered as atypical antipsychotics were aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone. Participants taking atypical antipsychotics were stratified according to the drug prescribed, dose and the number of days of exposure during the year before the index date. Analyses were adjusted for the overall burden of comorbidities (assessed using the Charlson Comorbidity Index) during the preindex period, and specific comorbidities including diabetes (in the hyperlipidaemia study), hyperlipidaemia (in the diabetes study), hypertension, obesity, dementia, depression, anxiety and adjustment disorders. The hyperlipidaemia study additionally adjusted for stroke, coronary heart disease or ischaemic heart disease as indicators for cardiovascular disease.

**Outcomes**: Incident onset of treatment-dependent diabetes or hyperlipidaemia.

**Methods**

*Design*: Two case control studies.

*Follow-up period*: One year.

**Main results**

During the preindex period, 1.3% of diabetes cases had been exposed to an atypical antipsychotic compared with 0.8% of controls (OR 1.32, 95% CI 1.10 to 1.59). A greater overall burden of comorbidity, diagnosis or treatment of hyperlipidaemia or hypertension, and diagnosis of obesity or dementia were all associated with increased odds of initiating diabetes treatment, while an anxiety diagnosis was associated with decreased odds of initiating diabetes treatment. In the hyperlipidaemia study, 0.8% of cases had been exposed to an atypical antipsychotic during the preindex period compared with 1.0% of controls (OR 0.76, 95% CI 0.67 to 0.87). Greater burden of comorbidity, diagnosis or treatment of diabetes, depression, obesity or cardiovascular disease during the preindex period was associated with increased odds of initiating hyperlipidaemia treatment. A diagnosis of dementia or adjustment disorders was associated with decreased odds of initiating hyperlipidaemia treatment.

**Conclusions**

In older adults, treatment with atypical antipsychotics for conditions other than schizophrenia and bipolar disorder is associated with increased odds of incident medication use for diabetes, and reduced odds of incident medication use for hyperlipidaemia.

**Abstracted from**


**Correspondence to**: Sara C Erickson, Sr. Outcomes Researcher, OptumRx, 2300 Main St. CA134-0404, Irvine, CA 92614, USA; sara.c.erickson@optum.com

**Sources of funding** Not reported.

**Notes** Notes and References are published online at http://ebmh.bmj.com

**Commentary**

Nicholson et al used data from multiple insurance companies to examine the risk of diabetes mellitus and hyperlipidaemia in older adults without schizophrenia or bipolar disorder who received treatment with atypical antipsychotic agents. This is an important study as it highlights the risk of metabolic disturbances in older adults treated with these agents. It also provided evidence that the increased risk for diabetes is not associated with the psychiatric diagnosis, but more so with the atypical antipsychotic agents themselves. The findings contradict a previous, smaller retrospective study that found no increased risk for diabetes in older patients treated with these agents. The results seem to fit more with clinical observation, which contrasts previous reports.

While the claims data methods used in this study have its limitations, the large sample size and comparison group increases its strength. The lack of association with these agents and hyperlipidaemia is not surprising. The risk of hyperlipidaemia associated with the atypical antipsychotic agents lies mostly in their effects on insulin resistance which can impair lipid metabolism primarily through lowering high-density lipoprotein cholesterol and increasing triglycerides. However, these two lipid abnormalities are less likely to result in the diagnosis of hyperlipidaemia or the recommendation of a lipid lowering drug. Even more so, the first-line treatment for elevated triglycerides is commonly the recommendation of diet and ω-3 fatty acid treatment such as fish oil and does not necessitate a prescription.

The results of this study should inform clinicians of the need for close monitoring for diabetes mellitus in patients treated with these agents. Though difference between agents was not observed, the study highlights the importance of monitoring all patients treated with atypical antipsychotic agents and that an advanced age is not protective from the metabolic effects.

Neelam Thakurathi, David C Henderson
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

**Competing interests** None.
Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder

Evid Based Mental Health 2012 15: 61 originally published online June 22, 2012
doi: 10.1136/ebmental-2012-100740

These include:

References
This article cites 2 articles, 0 of which you can access for free at:
http://ebmh.bmj.com/content/15/3/61#BIBL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (8)
Schizophrenia spectrum (430)
Bipolar disorder (236)
Drugs: psychiatry (344)
Adjustment disorders (9)
Neurology (1070)
Epidemiologic studies (631)
Epidemiology (1570)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/